Can a common diabetes drug shield transplanted kidneys?
NCT ID NCT04906213
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug empagliflozin (a diabetes medicine) in 20 people who had a kidney transplant, some with type 2 diabetes and some without. The goal was to see if the drug could help protect their heart and kidney function. The trial was stopped early, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (a diabetes drug that helps protect the heart and kidneys)
What this could lead to
If it works, this could point toward a way to protect heart and kidney health in kidney transplant recipients, especially those with type 2 diabetes.
What could go wrong
This was a small, early-phase trial that was terminated early, so results are limited. The drug may increase the risk of urinary or genital infections in this population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States